Drug intelligence / Profile preview

LPT-401

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules
Administration: Oral

Overview

LPT-401 is a preclinical-stage drug candidate being developed by LitePharmTech for the treatment of diarrhea. It is categorized as a "super generic," a term used to describe an improved formulation of an existing pharmaceutical product. These formulations are typically designed to enhance the pharmacokinetic profile, stability, or patient compliance of the original drug. As of early 2024, LPT-401 is in the preclinical phase of development, and specific details regarding its active ingredient or the nature of its formulation improvements have not been publicly disclosed.

Beyond the preview

Go deeper on LPT-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-401.

Explore the full profile